ARMOBIOX Human Albumin

Pharmacokinetics

• Under normal circumstances, the concentration of human albumin is 4 to 5 g/kg of body weight, with 40 to 45% intravascular and 55 to 60% extravascular.

• Abnormal distribution may occur in cases of severe burns or septic shock.

• The half-life of albumin averages approximately 19 days.

• Elimination occurs predominantly intracellularly via lysosomal proteases.

• Less than 10% of infused albumin leaves the intravascular compartment within the first 2 hours after infusion.

• The circulating volume increases 1 to 3 hours after administration.

• Balanced distribution between intravascular and interstitial spaces requires 48 hours.

• Human albumin is osmotically active and regulates circulating blood volume.

• When 50 mL of 20% human albumin is administered intravenously, approximately 175 mL of fluid is returned to circulation within 15 minutes.

• The degree of plasma expansion depends on initial blood volume.

• The risk of transmitting hepatitis is minimal with human albumin, and blood compatibility testing is not required.

Therapeutic Indications

• Increasing oncotic pressure in cases of oncotic deficiency

• Therapy for albumin deficiency

• Emergency treatment of shock and similar states requiring rapid blood volume restoration

• Treatment of burns

• Hypoproteinemia with or without edema

Available Presentations

Composition

Electrolytes